CBO says bipartisan Rx Drug Pricing Act would save more than $94 billion in the first decade

19 March 2020

The US Prescription Drug Pricing Reduction Act introduced by Senators Charles Grassley (Republican, Iowa) and Ron Wyden (Democrat, Oregon) could generate over $94 billion in savings over the next decade if enacted, according to an analysis from the Congressional Budget Office.

The bill has been on the Senate's legislative calendar for months, but it is unclear when it might get a vote. Full story: Healthcare Finance.

The CBO estimates that the legislation would reduce spending on cost-sharing by about $72 billion over the 2020-2030 period among Part D enrollees who are not covered by the Low-Income Subsidy program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK